Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis

Published:2021-07 Issue:3 Volume:73 Page:
ISSN:2724-6051
Container-title:Minerva Urology and Nephrology
language:
Short-container-title:Minerva Urol Nephrol

Author:

MA Chengquan,ABEYSEKERA Iruni R.,XU Wenbin,WANG Ying,PENG Jia,LI Hongjun

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2021N03A0276

Reference32 articles.

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer;Denis L, Murphy GP;Cancer,1993

2. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

3. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK

4. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer

5. Perpetuating effects of androgen deficiency on insulin resistance

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk;Clinical Pharmacology in Drug Development;2024-05-17

2. Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial;The Prostate;2024-02-04

3. Adverse events related to darolutamide treatment: analysis of "real life" data from EudraVigilance and the Food and Drug Administration database entries;Minerva Urology and Nephrology;2023-09

4. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis;Frontiers in Endocrinology;2023-03-31

5. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?;Journal of Clinical Oncology;2022-12-20